B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings
Caroline K Bundi, Olivia Muñoz, Elizabeth Kibwana, Duncan Bellamy et autres
1 citationFrontiers in Immunology
Domtila Kimani
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
82Publications signalées
1557Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Malaria Research and ControlSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingMosquito-borne diseases and controlCOVID-19 diagnosis using AI
Publications récentes
Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial
Melissa C. Kapulu, Francesca Orenge, Domtila Kimani, Elizabeth Kibwana et autres
1 citationNature Medicine
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings
Caroline K Bundi, Olivia Muñoz, Elizabeth Kibwana, Duncan Bellamy et autres
1 citationmedRxiv
R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial
Elizabeth Kibwana, Caroline K Bundi, Domtila Kimani, Lydia Nyamako et autres
5 citationsFrontiers in Immunology
Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial
Caroline K Bundi, Duncan Bellamy, Elizabeth Kibwana, Lydia Nyamako et autres
3 citationsFrontiers in Immunology
Quantification of Plasmodium falciparum: validation of quantitative polymerase chain reaction assays for detection of parasites in controlled human malaria infection studies
Elizabeth Kibwana, Domtila Kimani, Nick J. Edwards, Kelvias Keter et autres
4 citationsFrontiers in Malaria
R21/Matrix-M Protects Against Dermal but not Against Venous Parasites in Human Challenge Studies
Melissa C. Kapulu, Francesca Orenge, Domtila Kimani, Elizabeth Kibwana et autres
2 citationsmedRxiv
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya
Samuel Sang, Mehreen S Datoo, Edward Otieno, Charles Muiruri et autres
18 citationsWellcome Open Research
Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Samuel Sang, Mehreen Datoo, Edward Otieno, Charles Muiruri et autres
1 citationHarvard Dataverse
Maintaining laboratory quality assurance and safety in a pandemic: Experiences from the KEMRI-Wellcome Trust Research Programme laboratory’s COVID-19 response
Horace Gumba, Michael Opiyo, Jennifer Musyoki, Martin Mutunga et autres
0 citationsWellcome Open Research
An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams
Khadija Said Mohammed, Zaydah R. de Laurent, Donwilliams O. Omuoyo, Clement Lewa et autres
6 citationsWellcome Open Research
Spatio-temporal distribution of antimalarial drug resistant gene mutations in a Plasmodium falciparum parasite population from Kilifi, Kenya: A 25-year retrospective study
Irene Omedo, Brian Bartilol, Domtila Kimani, Sónia Gonçalves et autres
23 citationsWellcome Open Research
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.